Immnuocellular, IMUC, Profile, Summary

Immnuocellular Therapeutics | IMUC | Profile | Summary
 

ImmunoCellular Therapeutics is developing immune-based therapies for the treatment of brain cancer and other tumors. Our lead product candidate, ICT-107, is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. Our pipeline also includes ICT-121, a dendritic cell (DC) vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.
 

ImmunoCellular Therapeutics aims to become an industry-leading, independent, commercial-stage cancer immunotherapy company serving patients in major markets.

ImmunoCellular Cancer Vaccine Manufacturing Process

Each of ImmunoCellular’s dendritic cell (DC) vaccines is prepared from blood collected from each patient. The process, which takes only a few days to complete, is designed to generate sufficient cryopreserved (frozen) cells for dosing through the induction and maintenance phases of immunotherapy. Our GMP manufacturing process adheres strictly to standard operating procedures to ensure consistency, quality and sterility.

The process begins with an apheresis (also referred to as leukapheresis), a common procedure in which the patient’s blood is circulated through a machine to collect the white blood cells.

ImmunoCellular Therapeutics’ proprietary cancer vaccine immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatments than conventional cancer therapies. Our dendritic cell (DC)-based immunotherapies are designed to target both tumor cells as well as cancer stem cells by utilizing multiple tumor-specific antigens to trigger a powerful antitumor immune system response. Utilizing an advanced manufacturing process, we can produce multiple doses from a single apheresis, and offer the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared to earlier generation cancer vaccines.

Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:

• Potency

  • Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.

  • More than 80% of the final manufactured product consists of matured DCs.

• Versatility

  • Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.

• Efficiency

  • Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.

• Cost-effectiveness

  • Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.

• Convenience

  • Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.

  • Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.

Source: IMUC, OxBridge Research, Daily Stock Deal, OTCking

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

Disclaimer/Disclosure: we receive compensation from companies we feature on our websites/blogs/emails/newsletters or comment on social media/FB/TWTR etc. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Dialogic, DLGC, Profile, Summary

Dialogic | DLGC | Profile | Summary

Dialogic (DLGC) develops products and technologies that enable operators to provide – and subscribers to enjoy - an enhanced mobile experience. Whether our products are used in mobile value-added service solutions or to transform, connect and optimize communications services on a wide variety of networks, Dialogic understands that “mobile experience matters.™” Our technology touches two billion mobile subscribers a day, and our network solutions carry 15 billion minutes of traffic per month.

Dialogic, the Network Fuel™ company, inspires the world’s leading service providers and application developers to elevate the performance of media-rich communications across the most advanced networks. We boost the reliability of any-to-any network connections, supercharge the impact of applications and amplify the capacity of congested networks. Forty-eight of the world’s top 50 mobile operators and nearly 3,000 application developers rely on Dialogic to redefine the possible and exceed user expectations.

High performance networks and applications demand Network Fuel in the following areas:

Any to Any Networking:

Dialogic seamlessly and efficiently connecting disparate networks and/or value-added services platforms based on a complex array of networks and network protocols such as TDM, IP, SIP and IMS. Dialogic technologies enable media-rich communications, including video, voice and data, to flow uninterrupted between Service Providers and Application Developers and their end-users while ensuring the lowest operating costs and most optimal customer experience.

Contact Center Transformation:

As contact centers transition from TDM to IP, from premise-based to cloud/hosted or from fragmented to centralized to decentralized, Dialogic technologies enable contact center operators to maximize their investment by integrating multi-modal media-rich communications in a secure and optimized fashion. Contact centers empowered by Dialogic technologies perform better and run more cost effectively.

Unified Communications for Service Providers:

Through unique partnerships with market leaders in Unified Communications, Dialogic is enabling Service Providers to better leverage their investments in network switching infrastructure and offer a broader array of value-added services including hosted IP-PBX via PC and mobile, video calling and more sophisticated Class 5 services over a more secure and cost-optimized network. This collaboration enables Service Providers to more effectively compete with traditional Enterprise telephony vendors while expanding customer share of wallet.

Application Enablement:

The company is a recognized leader in software-based solutions that enable Application Developers to rapidly develop and monetize a wide array of value-added services such as messaging, SMS, video calling, ringtones, lawful intercept and location-based services. Dialogic customers are able to continually offer innovative solutions and benefit from our extensive capabilities in mixing media-rich communications, transitioning to virtualized or cloud-based architectures and deploying highly available and scalable platforms or services. The Dialogic Solution Showcase features market-tested, revenue generating solutions for service providers and enterprises. Each solution is recognized for its innovative nature as well as its market-proven reliability, ease of deployment and scalability. 
 

Source: Dialogic, OxBridge Research, Daily Stock Deal, OTC King

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

Disclaimer/Disclosure: we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.